Abstract:THESIS 11122%%%%The objective of this project was to explore clinical and molecular aspects of electroconvulsive therapy (ECT) in the treatment of depression, with a particular focus on the role of microRNAs (small, non-coding molecules that can regulate gene expression). The patients receiving ECT in this study were participants in a randomised controlled trial (the EFFECT-Dep Trial) of high-dose (6x seizure threshold) right unilateral and standard dose (1.5x seizure threshold) bitemporal brief-pulse ECT for depression. The objective of the EFFECT-Dep Trial was to compare the effectiveness and cognitive side-effects of these two forms of ECT. In this thesis, a systematic review and meta-analysis was carried out with a similar objective. PubMed, PsycInfo, Web of Science, Cochrane Library, Embase and the International Clinical Trials Registry Platform databases were searched for with the terms "electroconvulsive" or "electroshock" and "trial". Seven randomised controlled trials (n=792) met inclusion criteria, including the EFFECT-Dep Trial. Bitemporal ECT did not differ from high-dose unilateral ECT on depression rating change scores (Hedges?s g = -0.03; 95% confidence interval (CI) -0.17 to 0.11), remission (RR 1.06; 95% CI 0.93 to 1.20), or relapse at 12-months (RR 1.42; 95% CI 0.90 to 2.23). There was an advantage for unilateral ECT on reorientation time after individual ECT sessions (mean difference in minutes = -8.28; 95% CI -12.86 to -3.70) and retrograde autobiographical memory (Hedges?s g =-0.46, 95% CI=-0.87 to -0.04) after completing an ECT course. There were no differences for general cognition, category fluency and delayed visual and verbal memory. The immediate clinical implication of this is that high-dose right unilateral ECT should be considered as a first-line option when prescribing ECT. Peripheral blood samples from patients participating in the EFFECTDep Trial and healthy controls were collected in PaxGene? bottles. MicroRNAs and mRNAs were extracted using PaxGene? blood miRNA/RNA kits. An initial discovery phase deep sequencing study (n=16) was carried out on the SOLiD? platform. This yielded over 23 million reads mapping on to known microRNAs in the human genome. However, in the group as a whole there were no significant differences in microRNA levels from baseline to ECT following strict correction for multiple testing. However, post-hoc analysis indicated that there were significant changes in microRNA levels in patients with psychotic depression. These changes were confirmed in the same sample using quantitative real-time polymerase chain reaction (qRTPCR). In a separate cohort (37 depressed, 34 controls), candidate microRNAs from deep sequencing were analysed in a validation study. Two microRNAs (miR-126-3p and miR-106a-5p) were significantly elevated in patients with psychotic depression (n=7) at baseline when compared to healthy controls. After ECT treatment, the levels of these microRNAs normalised. Bioinformatic analysis revealed a high number of genes, molecular and biological processes…

Serum Angioneurin Levels Following Electroconvulsive Therapy for Mood Disorders

Brain-derived neurotrophic factor blood levels after electroconvulsive therapy in patients with mental disorders: A systematic review and meta-analysis

Increased Serum Brain-Derived Neurotrophic Factor Levels Following Electroconvulsive Therapy or Antipsychotic Treatment in Patients with Schizophrenia.

Effects of Neuronavigation-Guided Rtms on Serum BDNF, TrkB and VGF Levels in Depressive Patients with Suicidal Ideation

Blood biomarkers of neuronal injury and astrocytic reactivity in electroconvulsive therapy

Amygdala and hippocampal substructure volumes and their association with improvement in mood symptoms in patients with mood disorders undergoing electroconvulsive therapy

Electroconvulsive Therapy Changes Immunological Markers in Patients With Major Depressive Disorder

Exploring the effects of erythropoietin treatment on cortical thickness and hippocampal volume in patients with mood disorders undergoing electroconvulsive therapy: A randomized, placebo-controlled trial

The Level of Serum Brain-Derived Neurotrophic Factor is Associated with the Therapeutic Efficacy of Modified Electroconvulsive Therapy in Chinese Patients with Depression

Altered In vivo early neurogenesis traits in patients with depression: Evidence from neuron-derived extracellular vesicles and electroconvulsive therapy

Peripheral blood microRNA and VEGFA mRNA changes following electroconvulsive therapy: implications for psychotic depression

Elevated serum levels of FGF-2, NGF and IGF-1 in patients with manic episode of bipolar disorder.

Effect of Modified Electroconvulsive Therapy on Serum Brain-derived Neurotrophic Factor Levels in Patients with Major Depression

Biomarkers for Antidepressant Efficacy of Electroconvulsive Therapy: An Exploratory Cerebrospinal Fluid Study

Nodal degree changes induced by electroconvulsive therapy in major depressive disorder: Evidence in two independent cohorts

Epidermal Growth Factor in the Brain: A Promising Biomarker for Depression

Electroconvulsive therapy regulates brain connectome dynamics in patients with major depressive disorder

Nerve Growth Factor Variations in Patients with Mood Disorders: No Changes in Eight Weeks of Clinical Treatment.

Electroconvulsive therapy for depression : optimising treatment and exploring molecular mechanisms

Effect of Electroconvulsive Therapy on Medial Prefrontal Γ-Aminobutyric Acid among Schizophrenia Patients

Neuroplasticity-Related Genes and Dopamine Receptors Associated with Regional Cortical Thickness Increase Following Electroconvulsive Therapy for Major Depressive Disorder